أرسل هذا في رسالة قصيرة: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

           _    _                ___      ______  
  ____    | || | ||     ___     / _ \\   /_   _// 
 |    \\  | || | ||    /   ||  / //\ \\    | ||   
 | [] ||  | \\_/ ||   | [] || |  ___  ||  _| ||   
 |  __//   \____//     \__ || |_||  |_|| /__//    
 |_|`-`     `---`       -|_|| `-`   `-`  `--`     
 `-`                     `-`